Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Progenics Pharmaceuticals Inc | 19 |
| 2 | Cornell University | 16 |
| 3 | German Cancer Research Center | 10 |
| 4 | Novartis AG | 9 |
| 5 | Johns Hopkins University | 8 |
| 6 | Albert Ludwigs Universität Freiburg | 7 |
| 7 | University of California, San Diego | 7 |
| 8 | Curium US LLC | 6 |
| 9 | Amgen Inc | 5 |
| 10 | The University of Texas System | 4 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 194 |
| 2 | A61P | Therapeutic activity (drug indications) | 138 |
| 3 | C07D | Heterocyclic compounds | 66 |
| 4 | C07B | General methods of organic chemistry | 61 |
| 5 | C07K | Peptides | 44 |
| 6 | G06T | 40 | |
| 7 | A61B | 33 | |
| 8 | C07F | Organometallic compounds | 31 |
| 9 | G16H | Digital health, healthcare informatics | 29 |
| 10 | C07C | Acyclic and carbocyclic compounds | 26 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Prostate Cancer Treatment and Research | 9 |
| 2 | Glioma Diagnosis and Treatment | 1 |
| 3 | Radiopharmaceutical Chemistry and Applications | 1 |
| 4 | Renal cell carcinoma treatment | 1 |
| 5 | Sarcoidosis and Beryllium Toxicity Research | 1 |
| 6 | Thyroid Cancer Diagnosis and Treatment | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Matthias Eiber | Technical University of Munich | 41 |
| 2 | Ali Afshar‐Oromieh | University Hospital Heidelberg | 29 |
| 3 | Jérémie Calais | University of California, Los Angeles | 26 |
| 4 | Wolfgang P. Fendler | Essen University Hospital | 23 |
| 5 | Benedikt Kranzbühler | University of Zurich | 10 |
| 6 | Boris Hadaschik | Essen University Hospital | 19 |
| 7 | Louise Emmett | St Vincent's Hospital Sydney | 18 |
| 8 | Francesco Ceci | University of Bologna | 16 |
| 9 | Uwe Haberkorn | Heidelberg University | 15 |
| 10 | Andrea Farolfi | University of Bologna | 14 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Gallium Ga-68 gozetotide?
Which organizations hold the most patents related to Gallium Ga-68 gozetotide?
What are the primary clinical applications documented in the literature?
Who are the leading researchers publishing on this compound?
What is the current research activity trend for this compound?